Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2002-03-01
Target enrollment:
Participant gender:
Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 180
mg Fexofenadine Hydrochloride tablets manufactured for TEVA Pharmaceuticals Industries, Ltd.
with that of 180 mg ALLEGRA® Tablets by Aventis Pharmaceuticals, Inc. following a single oral
dose (1 x 180 mg tablet) in healthy adult volunteers under fasting conditions.